Cited by 126Alzheimer's disease research and treatmentsMedicinal Plants and NeuroprotectionCholinesterase and Neurodegenerative Diseases

The Role of Natural Products in the Discovery of New Drug Candidates for the Treatment of Neurodegenerative Disorders II: Alzheimers Disease

Divino da Rocha, Miguel, Pereira Dias Viegas, Flavia, Cristina Campos, Helineide, Carolina Nicastro, Patricia, Calve Fossaluzza, Poliana, Alberto Manssour Fraga, Carlos, J. Barreiro, Eliezer, Viegas, Claudio·2011·CNS & Neurological Disorders - Drug Targets

Abstract

The present review is part II in a series (part I focuses on Parkinson's Disease) that addresses the value of natural product chemistry in the discovery of medicines for the treatment of neurodegenerative disorders. Data reviewed document that a host of products from plant species and derivatives have neuroprotectant effects in vitro and in vivo. In addition, besides neuroprotection, natural products also demonstrate biological effects that target biochemical pathways underlying associated symptoms of neurdegnerative disorders that include cognitive impairments, energy/fatigue, mood, and anxiety. This part of the review series focuses specifically upon Alzheimer's Disease (AD). AD is postulated to result from extracellular formation of amyloid plaques and intracellular deposits of neurofibrilary tangles in the hippocampus, cerebral cortex and other areas of the brain essential for cognitive function. Plaques are formed mostly from the deposition β-amyloid (Aβ), a peptide derived from the amyloid precursor protein (APP). Filamentous tangles are formed from paired helical filaments composed of neurofilament and hyperphosphorilated tau protein, a microtubule-associated protein. In addition, environmental factors can engender the production of cytokines that are closely related to the installation of an inflammatory process that contributes to neuronal death and the development and the progression of AD. In this review we focus on the recent main contribuitions of natural products chemistry to the discovery of new chemical entities usefull to the control and prevention of AD installation and progression. More than sixteen plant species, including Ginseng, Celastrus paniculatus, Centella asiatica, Curcuma longa, Ginkgo biloba, Huperzia serrata, Lycoris radiate, Galanthus nivalis, Magnolia officinalis, Polygala tenuifolia, Salvia lavandulaefolia, Salvia miltiorrhiza, Coptis chinensis, Crocus sativus, Evodia rutaecarpa, Sanguisorba officinalis, Veratrum grandiflorum and Picrorhiza kurvoa, are discussed as potential sources of active extracts. In addition, more than sixty secondary metabolites are under evaluation for their efficacy on controlling symptoms and to impede the development and progression of AD.

Integrity signals

Registry

Crossref · 10.2174/187152711794480429

Cites

291 of 291 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Centella asiatica may have a role in Alzheimer's disease treatment and prevention.

    “In vitro research studies utilizing madasiatic acid, madecassoside, asiatic acid, and asiaticosides C. asiatica derivatives have elucidated that these compounds have the ability to block hydrogen peroxide and beta-amyloid-induced cellular death, as well as to reduce the concentration of free radicals, thereby proposing a possible role for C. asiatica in AD treatment and prevention [64,132,133].”

Cites

1 retracted

Flagged first, then by citations

3 of the 294 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Authors
Divino da Rocha, M., Pereira Dias Viegas, F., Cristina Campos, H., Carolina Nicastro, P., Calve Fossaluzza, P., Alberto Manssour Fraga, C., J. Barreiro, E., & Viegas, C.
Venue
CNS & Neurological Disorders - Drug Targets
Published
2011-03-01
Volume
10
Issue
2
Pages
251-270
ISSN
  • 1568-007X (ISSN-L)
  • 1871-5273
OpenAlex
W2146833115
Cited by
126
References
294
Citations by year
2026: 2 · 2025: 3 · 2024: 5 · 2023: 7 · 2022: 5 · 2021: 11 · 2020: 18 · 2019: 7 · 2018: 13 · 2017: 6 · 2016: 9 · 2015: 8 · 2014: 12 · 2013: 8 · 2012: 10
FWCI
6.76
Type
journal article
Language
en
Open access
closed
Locations
  • CNS & Neurological Disorders - Drug Targets (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Complementary and alternative medicine › Medicinal Plants and Neuroprotection
  • Health Sciences › Medicine › Pharmacology › Cholinesterase and Neurodegenerative Diseases
Keywords
Alzheimer's disease, natural products, phytochemicals, neuroprotection, amyloid plaques, amyloid-beta, tau protein, neurofibrillary tangles, neuroinflammation, secondary metabolites, drug discovery, ginseng, Salvia miltiorrhiza, turmeric, Ginkgo biloba, Huperzia serrata, Centella asiatica, Celastrus paniculatus, Magnolia officinalis, Polygala tenuifolia, Picrorhiza kurroa, cognitive impairment, mood and anxiety
MeSH terms
Alzheimer Disease, Biological Products, Central Nervous System, Humans, Neuroprotective Agents, Neurodegenerative Diseases, Drug Discovery, Molecular Targeted Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review